white 384-well polystyrene plate (Corning Life Sciences)
90
Structured Review
Corning Life Sciences
white 384-well polystyrene plate
White 384 Well Polystyrene Plate, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/white+384-well+polystyrene+plate/96+well+plates/pm40407274-234-10-13
Average 90 stars, based on 1 article reviews
White 384 Well Polystyrene Plate, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/white+384-well+polystyrene+plate/96+well+plates/pm40407274-234-10-13
Average 90 stars, based on 1 article reviews
white 384-well polystyrene plate - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer Therapy. Article Snippet: AXL receptor tyrosine kinase (AXL), a transmembrane protein highly expressed in a variety of cancers, has been implicated in the development of resistance to various forms of therapy and poor patient outcomes.. Although several strategies have been postulated to limit AXL signaling and thus tumor growth, further refinement is possible.. In this Drug Annotation, we report the structure-based design, SAR-driven optimization, preclinical pharmacokinetics (PK), and synthetic chemistry which enabled the discovery of AB801. Article Title: Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors. Article Snippet: High expression of the membrane-bound receptor tyrosine kinase AXL is linked to poor patient outcomes and therapeutic resistance in a variety of cancers.. Selective inhibition of AXL is a promising approach to overcome mechanisms of resistance to standard of care therapies, but it is unclear if reported inhibitors have achieved an appropriate therapeutic window to effectively block AXL signaling in tumors.. Herein, we report the initial design and structure−activity relationship (SAR)-driven optimization of a novel series of 7-azaindazole AXL inhibitors. |